Exposure to these types of endocrine chemical disruptors during pregnancy could alter the proliferative activity and cell potency in both populations of NSPCs, but their effects could be reflected only later in life
Safety Considerations and When to Discuss Dose Adjustments Severe nausea, vomiting, or acute gastrointestinal symptoms warrant immediate provider contact
Not everyone taking GLP-1 medications will develop gallstones, and the risk is generally considered to be very low (0.8%) (1)
For example, in 2023, the European Medicines Agency began investigating over 150 reports of suicidal ideation and other psychiatric symptoms linked to GLP-1 receptor agonists, including Ozempic and Wegovy
The goal is to create a gentler experience while still supporting metabolic health and appetite regulation
Pigment pathway switching